Hypoparathyroidism-Pipeline Review, H1 2015

Hypoparathyroidism-Pipeline Review, H1 2015

  • Products Id :- GMDHC6804IDB
  • |
  • Pages: 43
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Hypoparathyroidism-Pipeline Review, H1 2015


Global Markets Direct's, 'Hypoparathyroidism-Pipeline Review, H1 2015', provides an overview of the Hypoparathyroidism's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hypoparathyroidism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypoparathyroidism and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Hypoparathyroidism

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Hypoparathyroidism and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Hypoparathyroidism products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Hypoparathyroidism pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Hypoparathyroidism

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Hypoparathyroidism pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Hypoparathyroidism Overview 6

Therapeutics Development 7

Pipeline Products for Hypoparathyroidism-Overview 7

Pipeline Products for Hypoparathyroidism-Comparative Analysis 8

Hypoparathyroidism-Therapeutics under Development by Companies 9

Hypoparathyroidism-Pipeline Products Glance 10

Late Stage Products 10

Clinical Stage Products 11

Early Stage Products 12

Hypoparathyroidism-Products under Development by Companies 13

Hypoparathyroidism-Companies Involved in Therapeutics Development 14

Chugai Pharmaceutical Co., Ltd. 14

Rhein-Minapharm Biogenetics SAE 15

Shire Plc 16

Hypoparathyroidism-Therapeutics Assessment 17

Assessment by Monotherapy Products 17

Assessment by Target 18

Assessment by Mechanism of Action 20

Assessment by Route of Administration 22

Assessment by Molecule Type 24

Drug Profiles 26

Eu-232-Drug Profile 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

parathyroid hormone (recombinant)-Drug Profile 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

PCO-371-Drug Profile 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

Recombinant Protein to Agonize PTH-R for Hypoparathyroidism-Drug Profile 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

teriparatide-Drug Profile 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

Hypoparathyroidism-Recent Pipeline Updates 33

Hypoparathyroidism-Product Development Milestones 36

Hypoparathyroidism-Product Development Milestones 36

Featured News & Press Releases 36

Jan 23, 2015: FDA approves Natpara to control low blood calcium levels in patients with hypoparathyroidism 36

Dec 02, 2014: European Medicines Agency Validates Marketing Authorization Application for Natpar (parathyroid hormone (rDNA)) in Hypoparathyroidism 37

Oct 23, 2014: PDUFA Action Date For Natpara BLA Extended Three Months To January 24, 2015 37

Sep 12, 2014: FDA Advisory Committee Recommends Approval of Natpara for Long-Term Treatment of Hypoparathyroidism 38

Sep 12, 2014: FDA Advisory Committee to Review Natpara Biologics License Application 38

Sep 10, 2014: FDA Posts Briefing Materials for Advisory Committee Meeting Reviewing Natpara for Hypoparathyroidism 38

Jul 24, 2014: PARADOX Findings Published in Endocrine Practice Describe High Burden of Illness in Patients with Hypoparathyroidism 39

Jun 10, 2014: NPS Pharma Reports Change in Tentative Date of FDA Advisory Committee Review of Natpara BLA to September 12-PDUFA Date of October 24 Remains Unchanged 40

Jan 07, 2014: NPS Pharmaceuticals Announces FDA Acceptance of Biologics License Application for Natpara for the Treatment of Hypoparathyroidism 40

Jan 03, 2014: NPS Pharmaceuticals Receives Orphan Drug Designation for Natpara in Europe 41

Appendix 42

Methodology 42

Coverage 42

Secondary Research 42

Primary Research 42

Expert Panel Validation 42

Contact Us 42

Disclaimer 43

List of Tables

Number of Products under Development for Hypoparathyroidism, H1 2015 7

Number of Products under Development for Hypoparathyroidism-Comparative Analysis, H1 2015 8

Number of Products under Development by Companies, H1 2015 9

Comparative Analysis by Late Stage Development, H1 2015 10

Comparative Analysis by Clinical Stage Development, H1 2015 11

Comparative Analysis by Early Stage Development, H1 2015 12

Products under Development by Companies, H1 2015 13

Hypoparathyroidism-Pipeline by Chugai Pharmaceutical Co., Ltd., H1 2015 14

Hypoparathyroidism-Pipeline by Rhein-Minapharm Biogenetics SAE, H1 2015 15

Hypoparathyroidism-Pipeline by Shire Plc, H1 2015 16

Assessment by Monotherapy Products, H1 2015 17

Number of Products by Stage and Target, H1 2015 19

Number of Products by Stage and Mechanism of Action, H1 2015 21

Number of Products by Stage and Route of Administration, H1 2015 23

Number of Products by Stage and Molecule Type, H1 2015 25

Hypoparathyroidism Therapeutics-Recent Pipeline Updates, H1 2015 33

List of Figures

Number of Products under Development for Hypoparathyroidism, H1 2015 7

Number of Products under Development for Hypoparathyroidism-Comparative Analysis, H1 2015 8

Number of Products under Development by Companies, H1 2015 9

Comparative Analysis by Early Stage Products, H1 2015 12

Assessment by Monotherapy Products, H1 2015 17

Number of Products by Top 10 Targets, H1 2015 18

Number of Products by Stage and Top 10 Targets, H1 2015 18

Number of Products by Top 10 Mechanism of Actions, H1 2015 20

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 20

Number of Products by Top 10 Routes of Administration, H1 2015 22

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 22

Number of Products by Top 10 Molecule Types, H1 2015 24

Number of Products by Stage and Top 10 Molecule Types, H1 2015 24

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com

Chugai Pharmaceutical Co., Ltd.

Rhein-Minapharm Biogenetics SAE

Shire Plc

Hypoparathyroidism Therapeutic Products under Development, Key Players in Hypoparathyroidism Therapeutics, Hypoparathyroidism Pipeline Overview, Hypoparathyroidism Pipeline, Hypoparathyroidism Pipeline Assessment

select a license

Single User License
USD 2000 INR 132860
Site License
USD 4000 INR 265720
Corporate User License
USD 6000 INR 398580



The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...

Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@] kenresearch.com